Skip to main content
SpringerLink
Log in

Vitamin D and Prostate Cancer

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2930 Accesses

Abstract

Vitamin D was first recognized for its role in bone health. It is now known to have a number of important physiological effects, and vitamin D levels have been implicated in the pathology of a wide range of diseases including cardiovascular disease, hypertension, cancer, and autoimmune-based pathologies such as multiple sclerosis [1]. Aside from prostate cancer, vitamin D deficiency has also been linked to colorectal cancer [2], and there is evidence to suggest a role in skin and breast cancers. Elevated levels of vitamin D have been associated with worse outcomes from breast, esophagus, and pancreatic cancer [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wei MY, Giovannucci EL. Vitamin D and multiple health outcomes in the Harvard cohorts. Mol Nutr Food Res. 2010;54(8):1114–26.

    PubMed  CAS  Google Scholar 

  2. Lieberman DA, Prindiville S, Weiss DG, Willett W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290:2959–67.

    Article  PubMed  Google Scholar 

  3. Toner CD, Davis CD, Milner JA. The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc. 2010;110(10):1492–500.

    Article  PubMed  CAS  Google Scholar 

  4. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990;10:1307–11.

    PubMed  CAS  Google Scholar 

  5. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992;70:2861–9.

    Article  PubMed  CAS  Google Scholar 

  6. Vitamin D. Linus Pauling Institute Micronutrient Information Center. http://lpi.oregonstate.edu/infocenter/vitamins/vitaminD/. Accessed 13 Jan 2011.

  7. Lagunova Z, Porojnicu AC, Vieth R, et al. Serum 25-hydroxyvitamin D is a predictor of serum 1,25-dihydroxyvitamin D in overweight and obese patients. J Nutr. 2011;141(1):112–7.

    Article  PubMed  CAS  Google Scholar 

  8. Chen TC, Wang L, Whitlatch LW, et al. Prostatic 25-­hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem. 2003;88:315–22.

    Article  PubMed  CAS  Google Scholar 

  9. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet. 2001;357:1673–4.

    Article  PubMed  CAS  Google Scholar 

  10. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7:684–700.

    Article  PubMed  CAS  Google Scholar 

  11. Gill RK, Christakos S. Identification of sequence elements in mouse calbindin-D28k gene that confer 1, 25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc Natl Acad Sci USA. 1993;90:2984–8.

    Article  PubMed  CAS  Google Scholar 

  12. Nanes MS, Kuno H, Demay MB, et al. A single up-stream element confers responsiveness to 1, 25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene. Endocrinology. 1994;134:1113–20.

    Article  PubMed  CAS  Google Scholar 

  13. Liu M, Lee MH, Cohen M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10:142–53.

    Article  PubMed  CAS  Google Scholar 

  14. Maestro B, Davila N, Carranza MC, et al. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol. 2003;84:223–30.

    Article  PubMed  CAS  Google Scholar 

  15. Polly P, Carlberg C, Eisman JA, et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem. 1996;60:322–33.

    Article  PubMed  CAS  Google Scholar 

  16. Hakim I, Bar-Shavit Z. Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response ­element. J Cell Biochem. 2003;88:986–98.

    Article  PubMed  CAS  Google Scholar 

  17. Wharton B, Bishop N. Rickets. Lancet. 2003;362(9393):1389–400.

    Article  PubMed  CAS  Google Scholar 

  18. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777–83.

    Article  PubMed  CAS  Google Scholar 

  19. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.

    Article  PubMed  CAS  Google Scholar 

  20. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69(5):842–56.

    PubMed  CAS  Google Scholar 

  21. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.

    Article  PubMed  CAS  Google Scholar 

  22. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993;132(5):1952–60.

    Article  PubMed  CAS  Google Scholar 

  23. Schwartz GG, Oeler TA, Uskoković MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D ­analogs. Anticancer Res. 1994;14(3A):1077–81.

    PubMed  CAS  Google Scholar 

  24. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1 alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 1997;6(9):727–32.

    PubMed  CAS  Google Scholar 

  25. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997;50(6):999–1006.

    Article  PubMed  CAS  Google Scholar 

  26. Zheng Y, Zhou H, Ooi LL, et al. Vitamin D deficiency promotes prostate cancer growth in bone. Prostate. 2011;71:1012–21.

    Article  PubMed  CAS  Google Scholar 

  27. Beer TM, Hough KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol. 2001;28:49–55.

    Article  PubMed  CAS  Google Scholar 

  28. Hershberger PA, Yu WD, Modzelewski RA, et al. Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001;7:1043–51.

    PubMed  CAS  Google Scholar 

  29. Moffatt KA, Johannes WU, Miller GJ. 1Alpha, 25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999;5:695–703.

    PubMed  CAS  Google Scholar 

  30. Ahmed S, Johnson CS, Rueger RM, et al. Calcitriol (1, 25-­dihydroxycholecalciferol) potentiates activity of mitoxantrone/­dexamethasone in an androgen independent prostate cancer model. J Urol. 2002;168:756–61.

    Article  PubMed  CAS  Google Scholar 

  31. Dunlap N, Schwartz GG, Eads D, et al. 1alpha, 25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha, 25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer. 2003;89:746–53.

    Article  PubMed  CAS  Google Scholar 

  32. Bernardi RJ, Trump DL, Yu WD, et al. Combination of 1alpha, 25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res. 2001;7:4164–73.

    PubMed  CAS  Google Scholar 

  33. Gavrilov V, Steiner M, Shany S. The combined treatment of 1, 25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res. 2005;25:3425–9.

    PubMed  CAS  Google Scholar 

  34. Giovannucci E. Diet, 1,25(OH)2 vitamin D and prostate cancer: a hypothesis. Cancer Causes Control. 1998;9:567–83.

    Article  PubMed  CAS  Google Scholar 

  35. Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr. 2005;81(5):1147–54.

    PubMed  CAS  Google Scholar 

  36. Gonzalez CA, Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer. 2010;46(14):2555–62.

    Article  PubMed  Google Scholar 

  37. Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN. Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol. 2007;166(11):1259–69.

    Article  PubMed  Google Scholar 

  38. Ahn J, Albanes D, Peters U, et al. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007;16:2623–30.

    Article  PubMed  CAS  Google Scholar 

  39. Kristal AR, Arnold KB, Neuhouser ML, et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;172(5):566–77.

    Article  PubMed  Google Scholar 

  40. Chan JM, Pietinen P, Virtanen M, et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control. 2000;11(9):859–67.

    Article  PubMed  CAS  Google Scholar 

  41. Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer. 2008;60(4):421–41.

    Article  PubMed  Google Scholar 

  42. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4(3):e103.

    Article  PubMed  Google Scholar 

  43. Travis RC, Crowe FL, Allen NE, et al. Serum vitamin D and risk of prostate cancer in a case control analysis nested within the European prospective investigation into cancer and nutrition (EPIC). Am J Epidemiol. 2009;169:1223–32.

    Article  PubMed  Google Scholar 

  44. Ahn J, Peters U, Albanes D, for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team, et al. Serum vitamin D concentration and prostate cancer risk: a nested case–control study. J Natl Cancer Inst. 2008;100(11):796–804.

    Article  PubMed  CAS  Google Scholar 

  45. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case–control study in the Nordic countries. Int J Cancer. 2004;108(1):104–8.

    Article  PubMed  CAS  Google Scholar 

  46. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    Article  PubMed  Google Scholar 

  47. Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis. Cancer Causes Control. 2011;22:319–40.

    Article  PubMed  Google Scholar 

  48. de Vries E, Soerjomataram I, Houterman S, Louwman MW, Coebergh JW. Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation? Am J Epidemiol. 2007;165(8):966–72.

    Article  PubMed  Google Scholar 

  49. Colli JL, Grant WB. Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in United States. Urology. 2008;71(3):531–5.

    Article  PubMed  Google Scholar 

  50. Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high risk cohorts. Eur Urol. 1999;35:362–9.

    Article  PubMed  CAS  Google Scholar 

  51. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.

    Article  PubMed  CAS  Google Scholar 

  52. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.

    Article  PubMed  CAS  Google Scholar 

  53. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996;56(18):4108–10.

    PubMed  CAS  Google Scholar 

  54. Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol. 2006;175:1613–23.

    Article  PubMed  CAS  Google Scholar 

  55. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18:1929–33.

    Article  PubMed  CAS  Google Scholar 

  56. Luscombe CJ, Fryer AA, French ME, et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet. 2001;358:641–2.

    Article  PubMed  CAS  Google Scholar 

  57. Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res. 2006;26(4A):2647–51.

    PubMed  CAS  Google Scholar 

  58. Osborn JL, Schwartz GG, Smith DC, et al. Phase II trial of oral 1, 25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol. 1995;1:195–8.

    Article  PubMed  CAS  Google Scholar 

  59. Gross C, Stamey T, Hancock S, et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159:2035–9.

    Article  PubMed  CAS  Google Scholar 

  60. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001;91:2431–9.

    Article  PubMed  CAS  Google Scholar 

  61. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002;72:648–59.

    Article  PubMed  CAS  Google Scholar 

  62. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25:669–74.

    Article  PubMed  CAS  Google Scholar 

  63. Barnett C, Beer T. Vitamin D and prostate cancer. In: Trump D, Johnson C, editors. Vitamin D and cancer. New York: Springer; 2011. p. 221–49.

    Chapter  Google Scholar 

  64. Berkovich L, Ben-Shabat S, Sintov A. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog. Anticancer Drugs. 2010;21(6):609–18.

    Article  PubMed  CAS  Google Scholar 

  65. Attia S, Eickhoff J, Wilding G, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008;14:2437–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, East Sussex Hospitals NHS Trust, Conquest Hospital, The Ridge, St. Leonards-on-Sea, East Sussex, TN37 7RD, UK

    Naomi Smith M.A., M.B.B.S., MRCS

  2. Department of Urology, British Hospital of Buenos Aires and Austral University, Perdriel 74 Av. Juan Domingo Peron 1,500 (Pilar) Capital Federal, Buenos Aires, C1280AEB, Argentina

    Alejandro Nolazco M.D.

Authors
  1. Naomi Smith M.A., M.B.B.S., MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alejandro Nolazco M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naomi Smith M.A., M.B.B.S., MRCS .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Smith, N., Nolazco, A. (2013). Vitamin D and Prostate Cancer. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_31

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation